Revlimid News and Research

RSS

Velcade, lenalidomide and dexamethasone combo show promise for multiple myeloma

A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.

13 Dec 2007

Oral drug sets a new survival standard for bone marrow cancer

Findings from two large, international clinical trials show "unprecedented" survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow.

21 Nov 2007

Lenalidomide - dexamethasone combination effective against multiple myeloma

Pairing a new thalidomide derivative with a steroid slows progress of multiple myeloma, an incurable bone marrow cancer, and prolongs the lives of patients who have relapsed from previous treatment, researchers report in the Nov. 22 New England Journal of Medicine.

21 Nov 2007

Studies attribute recent increase in multiple myeloma survival to novel therapies

Multiple myeloma is one of the most common and devastating bone marrow cancers in the U.S., but survival rates have risen dramatically over the past decade.

2 Nov 2007

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Celgene International Sarl has announced that it's oral cancer drug, Revlimid (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

5 Sep 2007

Myeloma cancer drug gets the green light from the EU

The European Union has given the green light to a drug which doubles the survival rates for people with myeloma.

21 Jun 2007

Revlimid may change the way physicians treat multiple myeloma

Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG 4A03) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone.

5 Jun 2007

Patients with myelodysplastic syndromes treated with Revlimid are living longer and remaining transfusion independent

New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) were presented by Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, at the 9th International Symposium on MDS currently taking place in Florence, Italy.

18 May 2007

Multiple myeloma dexamethasone / lenalidomide trial closes

The Southwest Oncology Group, the largest of several National Cancer Institute-sponsored clinical trials networks, has permanently closed enrollment in a trial comparing a standard drug therapy, dexamethasone, with a combined therapy of the same drug plus the drug lenalidomide (Revlimid) for people newly diagnosed with multiple myeloma.

16 May 2007

Lower doses of dexamethasone for multiple myeloma recommended

The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said physicians should consider lowering the dose of the steroid dexamethasone when treating patients with multiple myeloma.

5 Apr 2007

Roswell Park research aids development of myeloma drug

Roswell Park Cancer Institute (RPCI) researchers played a leading role in clinical studies which led to U.S. Food and Drug Administration (FDA) approval of a new treatment for patients diagnosed with multiple myeloma - the second most common blood cancer.

11 Jul 2006

Natural killer cells and antibody-based immune function

A new drug may boost the effectiveness of a widely used treatment for patients with non-Hodgkin lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.

4 Apr 2006

FDA grants priority review for Revlimid

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory multiple myeloma.

6 Mar 2006

Thalomid gives hope for blood cancer sufferers

Drug company Celgene says it has halted a pivotal-stage trial of its Thalomid drug earlier than expected after the drug was shown to dramatically limit the progress of the blood cancer multiple myeloma.

9 Jan 2006

Rev/Dex combo looks like a breakthrough treatment for multiple myeloma

Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (Revlimid) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.

1 Sep 2005

Revlimid results look promising for multiple myeloma patients

The Multiple Myeloma Research Foundation (MMRF) applauded today's Celgene announcement regarding Revlimid, a new class of novel immunomodulatory drugs currently being evaluated to treat a broad range of hematology and oncology conditions, including multiple myeloma.

8 Mar 2005

Experimental drug Revlimid showing promise as treatment for myelodysplastic syndrome (MDS)

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia.

10 Feb 2005

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.

7 Dec 2004